YEM Search

搜索结果

QSOX1

靶点ID:TCMBANKGE005721

靶点别名:Q6; QSCN6

靶点描述:quiescin sulfhydryl oxidase 1

染色体:1

染色体位置:1q25.2

靶点类型:protein-coding

HERB_ID:-

HGNC_Link:9756

OMIM_Link:603120

Ensembl_Link:ENSG00000116260

靶点对应的植物

ID	拉丁名	药名	药用植物名	功能与主治	来源	药用部位	使用民族

靶点对应的化合物

化合物ID	化合物名	别名	分子式	分子质量	Smiles

TCMBANKIN033702	citric acid	InChI=1/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12; NCGC00090954-02; NCGC00090954-01; HSDB 911; CIT; Citric acid (8CI); BRN 0782061; NCIStruc2_000099; 27109_RIEDEL; AIDS-017733; 1,2,3-PROPANETRICARBOXYLIC ACID,2-HYDROXY (CITRIC ACID); citr; 27488_FLUKA; FEMA No. 2306; E 330; 27485_FLUKA; 27487_FLUKA; 77-92-9; C2404_SIGMA; 2-Hydroxytricarballylic acid; NCIOpen2_004502; F 0001 (polycarboxylic acid); EPA Pesticide Chemical Code 021801; AI3-06286; 245654-34-6; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-; Citretten; Kyselina citronova; 2-hydroxypropane-1,2,3-tricarboxylic acid; Anhydrous citric acid; Citrate standard for IC; C83155_SIAL; LS-2418; WLN: QV1XQVQ1VQ; 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI); NSC30279; .beta.-Hydroxytricarballylic acid; NSC 626579; FLC; NCI60_022579; LS-3185; 2-hydroxy-1,2,3-propanetricarboxylic acid; Caswell No. 221C; EINECS 201-069-1; 43136-35-2; 251275_SIAL; 38730_FLUKA; C4540_SIGMA; FEMA Number 2306; 4-03-00-01272 (Beilstein Handbook Reference); 3-Carboxy-3-hydroxypentane-1,5-dioic acid; Citric acid anhydrous (JAN); C00158; 12262-73-6; 240621_ALDRICH; AIDS017733; MLS001066346; Kyselina 2-hydroxy-1,2,3-propantrikarbonova [Czech]; 2-Hydroxypropanetricarboxylic acid; CCRIS 3292; KBio3_002740; NSC626579; D00037; SBB008922; Kyselina citronova [Czech]; Aciletten; NSC 30279; Anhydrous citric acid (JP15); 46933_SUPELCO; NCIOpen2_004062; Citric acid solution; CHEBI:30769; Citro; BSPBio_003240; NCIStruc1_000057; Uro-trainer; Citric acid, anhydrous (USP); W230618_ALDRICH; Citric acid [USAN:JAN]; H3cit; Chemfill; Hydrocerol A; Suby G; Oprea1_502996; Citric acid, anhydrous; SMR000471840; Citric acid anhydrous; Spectrum3_001850	C6H8O7	192.12	C(C(=O)O)C(CC(=O)O)(C(=O)O)O
TCMBANKIN059684	Vitamin E β-		C29H50O2	430.79	CC1=C(C(=C2CCC(OC2=C1C)(C)CCCC(C)CCCC(C)CCCC(C)C)C)O
TCMBANKIN059746	α-tocopherol		C29H50O2	430.7 g/mol	CC1=C(C2=C(CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C)C(=C1O)C)C
TCMBANKIN061943	dimethyl disulfide	(T)DIMETHYL DISULFIDE; 3P8D642K5E; Dimethyl disulphide; InChI=1/C2H6S2/c1-3-4-2/h1-2H; 2,3-Dithiabutane; Methyl disulfide (8CI); CCRIS 2939; Dimethyl disulfide, purum, >=98.0% (GC); CHEMBL1347061; WQOXQRCZOLPYPM-UHFFFAOYSA-N; MCULE-7451882535; Dimethyl disulfide, natural, >=98%, FG; F0001-1676; EINECS 272-923-9; methyl disulphide; NCGC00091798-01; NSC 9370; methyldisulfanyl methane; (Methyldisulfanyl)methane; NCGC00259075-01; METHYL DISULFIDE; RP18575; TL8004165; 595560-92-2; dimethydisulfide; dimethyldisulphide; UN 2381; (1/4)x>>u paragraph signthornAoAN; EN300-36043; DSSTox_CID_5117; (METHYLDISULFANYL)METHYL; DSSTox_RID_77673; EC 210-871-0; Dimethyl disulfide, >=99.0%; (Methyldisulfanyl)methane #; ZINC8221057; 624-92-0; CAS-624-92-0; Methyldisulfanylmethane; FT-0625135; (Methyldithio)methane; Dimethyl disulfide, analytical standard; LS-1499; C08371; Disulfide, dimethyl; Dimethyl disulfide, 99%; D0714; RTR-021489; NSC9370; NSC-9370; CTK2F3131; AN-22028; Dimethyl disulfide [UN2381] [Flammable liquid]; KB-76616; DSSTox_GSID_25117; I09-0129; MFCD00008561; AC1Q4HEQ; CHEBI:4608; Dimethyl disulfide, >=99%; AC1L1Z53; DMDS; UN2381; NCGC00091798-02; Dimethyl disulfide, 98%; Dimethyl disulfide [UN2381] [Flammable liquid]; DTXSID4025117; 224638-EP2371831A1; WLN: 1SS1; AI3-25305; A833808; Dimethyl disulfide; Q-100719; Dimethyl disulfide, >=98%, FG; 1,2-Dimethyldisulfane; UNII-3P8D642K5E; FEMA No. 3536; KS-000017OV; Tox21_201525; PubChem9665; BDBM233038; (CH3S)2; HSDB 6400; Methyldithiomethane; AC1Q4HER; AKOS009157459; TR-021489; EINECS 210-871-0; MeS-SMe; Dimethyldisulfide; MolPort-003-929-787; Methyldisulfide	C2H6S2	94.2 g/mol	CSSC

靶点对应的疾病

疾病ID	疾病名	MeSH名	HPO名	UMLS名	疾病类型

TCMBANKDI000076		Neoplasms	-	Neoplastic Process	group
TCMBANKDI003353		Pathological Conditions, Signs and Symptoms; Neoplasms	-	Neoplastic Process	phenotype
TCMBANKDI010239		Chemically-Induced Disorders; Mental Disorders	-	Mental or Behavioral Dysfunction	group
TCMBANKDI010395		Neoplasms	-	Neoplastic Process	disease
TCMBANKDI011743		Neoplasms; Skin and Connective Tissue Diseases	Neoplasm; Abnormality of the breast	Neoplastic Process	group
TCMBANKDI012506		Neoplasms	-	Neoplastic Process	disease
TCMBANKDI013628		Neoplasms; Skin and Connective Tissue Diseases	-	Neoplastic Process	disease
TCMBANKDI015256		Chemically-Induced Disorders; Mental Disorders	-	Mental or Behavioral Dysfunction	phenotype
TCMBANKDI017024		Neoplasms; Respiratory Tract Diseases	-	Neoplastic Process	disease
TCMBANKDI019879		Digestive System Diseases; Neoplasms; Endocrine System Diseases	-	Neoplastic Process	disease
TCMBANKDI022646		Digestive System Diseases; Neoplasms; Endocrine System Diseases	Abnormality of the digestive system; Neoplasm	Neoplastic Process	disease
TCMBANKDI024147		Chemically-Induced Disorders; Mental Disorders	-	Mental or Behavioral Dysfunction	group